In fact, if we look at it through a pragmatic lens, sustainability reflects how a company does what it does, with a focus on ...
While shares have posted break-even returns so far in 2024, Pfizer stock has cratered by more than 30% over the ...
Cigna said that Khan, along with Commissioners Rebecca Kelly Slaughter and Alvaro Bedoya, have made repeated and incorrect ...
Indianapolis: Eli Lilly and Company has announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, ...
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...
Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...
Thomas Fuchs will lead AI initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.
Board directors of Mars Area School District unanimously agreed to join a class action lawsuit against Eli Lilly and Company ...
A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.
Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...
Discover how Eli Lilly & Co. is focused on healthcare innovation by naming Thomas Fuchs, formerly of Mount Sinai Health System, its first chief AI officer.
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development facility in Lebanon, Indiana expected to open in late 2027. Fatty liver ...